Avelumab as a first- or second-line treatment for metastatic kidney cancer

A recent study looked at the efficacy and safety of first- or second-line avelumab (an anti–PD-L1 immunotherapy) in patients with metastatic clear cell renal cell carcinoma (RCC).

A total of 62 patients were treated with avelumab in the first-line (intravenous infusion every 2 weeks) and 20 patients were treated with avelumab in the second-line. Most patients had intermediate- to poor-risk RCC. Progression-free survival was 8.3 months for first-line treatment with avelumab and 5.6 months for second-line treatment, while overall survival was not evaluable for first-line use of avelumab and 16.9 months for second-line use. Responses were durable and occurred irrespective of PD-L1 status.

The results from this study were not clear as far as the use of avelumab on its own to treat metastatic RCC in the first-line, but support the use of avelumab in the second-line. Avelumab was safe in both the first- and second-line and these data support the use of avelumab in combination with other treatments for metastatic RCC.

Read more in Journal for ImmunoTherapy of Cancer here

Share this Post!


Related post

  TOP